All In Biotech

Drug Trial Radar · NCT00412984

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation

Last checked: Nov 19, 2026Latest source record: Jul 3, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 20,976 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

20,976

Actual

Start

Dec 31, 2006

Primary completion

May 25, 2011

Study completion May 25, 2011

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Dec 19, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The trial seeks to determine if apixaban, an investigational anticoagulant (blood-thinner) is as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in subjects with atrial fibrillation and risk factors for stroke.

Conditions

  • Atrial Fibrillation
  • Atrial Flutter

Interventions

  • warfarinDrug

    Oral tablets, 2.0 mg, adjusted to an INR of 2.5 (range 2.0 to 3.0)

  • apixabanDrug

    Oral tablets, 5.0 mg or 2.5 mg, twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With First Event of Ischemic/Unspecified Stroke, Hemorrhagic Stroke, or Systemic Embolism (SE) During the Intended Treatment PeriodTime frame: Time to first event in "Intended Treatment Period": started on day of randomization, ended at efficacy cut-off date (date target number of primary efficacy events [448] was expected to have occurred; set to 30-Jan-2011, prior to unblinding).
  2. Rate of Adjudicated Stroke or Systemic Embolism (SE) During the Intended Treatment PeriodTime frame: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).

Locations

1,111 sites in 41 countries. Site status is shown where the registry gives one.

  • Cardiovascular Associates, Pc

    Birmingham, Alabama

  • Alabama Internal Medicine Pc

    Birmingham, Alabama

  • Birmingham Heart Clinic P.C.

    Birmingham, Alabama

  • Heart Center, Inc.

    Huntsville, Alabama

  • Mobile Heart Specialists, Pc

    Mobile, Alabama

  • Clara V. Massey, Md

    Mobile, Alabama

  • Alaska Heart Institute

    Anchorage, Alaska

  • Internal Medicine Physicians Associates, P.C.

    Phoenix, Arizona

  • Southwest Heart

    Tucson, Arizona

  • Southern Arizona Va Health Care System

    Tucson, Arizona

  • Pima Research Foundation

    Tucson, Arizona

  • Dr. Rajesh Shroff

    Hot Springs, Arkansas

  • Mary K. Richards, Md Pa

    Little Rock, Arkansas

  • Advanced Clinical Reserach Institute

    Anaheim, California

  • Act/Cardiovascular Research Institute

    Beverly Hills, California

  • Capitol Interventional Cardiology

    Carmichael, California

  • Escondido Cardiology Associates, Inc.

    Escondido, California

  • William D. Bowden, D.O.

    Healdsburg, California

  • La Mesa Cardiac Center, A Medical Group

    La Mesa, California

  • Va Greater Los Angeles Healthcare System

    Los Angeles, California

  • Coastal Cardiology

    Mission Viejo, California

  • Kenneth W. Carr Md

    Oceanside, California

  • Desert Med Grp Inc, Dba Desert Oasis Healthcare Med Group

    Palm Springs, California

  • Desert Cardiology Consultants Medical Group, Inc

    Rancho Mirage, California

  • Regional Cardiolody Associates

    Sacramento, California

  • Northern California Research

    Sacramento, California

  • Sacramento Heart And Vascular Medical Associates

    Sacramento, California

  • Arrhythmia Consultants Of The Central Coast Medical Group

    Santa Barbara, California

  • Northern California Medical Associates

    Santa Rosa, California

  • Progressive Clinical Research

    Vista, California

  • Cardivasclular Consultants Medical Group

    Walnut Creek, California

  • Shiva Heart Center Medical Group

    Wildomar, California

  • Electrophysiology Associates, Pc

    Colorado Springs, Colorado

  • Aurora Denver Cardiology Associates, P.C.

    Denver, Colorado

  • Denver Va Medical Center

    Denver, Colorado

  • New West Physicians Clinical Research

    Golden, Colorado

  • South Denver Cardiology Associates Pc

    Littleton, Colorado

  • Connecticut Clinical Research, Llc

    Bridgeport, Connecticut

  • Bridgeport Hospital

    Bridgeport, Connecticut

  • Cardiology Associates Of New Haven,Pc

    Guilford, Connecticut

Showing 40 of 1,111 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.